uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted September 8, 2020

FDA Warns Seller of Opioid Withdrawal Supplement

On August 25, 2020, the FDA issued a warning letter to Renewal Supplements LLC following a review of the company's website, which found statements made about the company product Opi-Cure to be drug claims.

Opi-Cure was promoted with statements such as "Relieves withdrawal symptoms associated with opiate abuse" and "Opi-Cure is a unique supplement that contains root bark of the voacanga magnitola (voacanga africana) tree that contains the alkaloids voacangine and voaccamine which has been shown to be effective in the treatment of withdrawal symptoms and cravings associated with opiate dependence."

In addition, the product was found to be misbranded because it does not contain adequate directions for safe use, as required by federal regulations.

For more information, use the link below.

Warning Letter: Renewal Supplements LLC

See related warnings:

FDA Warns Seller of "All Natural" Treatment for Opioid Withdrawal, Migraines & More

Seller of Supplements for Opiate Withdrawal Warned for Drug Claims

FTC Charges Maker of Supplement for Opiate Addiction with Deceptive Claims